Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis c virus genotype 4 infection.

• Autores: Vandana Nehra, E.M Tan, Stacey A. Rizza, Zelalem Temesgen
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 52, Nº. 2, 2016, págs. 111-118
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Hepatitis C virus (HCV) genotype 4 accounts for 8-13% of all chronic HCV infections worldwide. Patients with HCV genotype 4 have been reported to have poor treatment responses to PEGylated interferon and ribavirin regimens. Recently a single tablet, fixed-dose combination of sofosbuvir, an RNA-directed RNA polymerase (NS5B) inhibitor, and ledipasvir, a nonstructural protein 5A (NS5A) inhibitor, has been approved for treatment of chronic HCV infection. Two studies using the fixed-dose combination in chronic HCV genotype 4 for 12 weeks reported sustained virologic response rates at 12 weeks (SVR12) of 93-95%. Data also support the use of ledipasvir/sofosbuvir in chronic HCV genotype 4 and HIV co-infection. Administered as a single once-daily oral regimen, this ribavirin- and interferon-free regimen is well tolerated, with low potential for adverse effects and represents a significant advancement in the treatment of chronic HCV genotype 4 infection.